Human genetics of intracellular infectious diseases: Molecular and cellular immunity against mycobacteria and salmonellae

Lancet Infectious Diseases

Volumn 4, Issue 12, 2004, Pages 739-749

  Vosse, Esther Van De ^a   Hoeve, Marieke A ^a   Ottenhoff, Tom H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 23;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; CELLULAR IMMUNITY; DISEASE PREDISPOSITION; GENE DELETION; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN GENETICS; IMMUNITY; LEISHMANIASIS; LEPROSY; MISSENSE MUTATION; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; NONSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SALMONELLA; TUBERCULOSIS; TYPHOID FEVER; VIRUS INFECTION;

CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; MYCOBACTERIUM INFECTIONS; PROTEIN SUBUNITS; RECEPTORS, INTERFERON; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-12; SALMONELLA INFECTIONS;

EID: 9644265521     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(04)01203-4     Document Type: Review

References (104)

1. Hill AVS. The immunogenetics of human infectious diseases. Annu Rev Immunol. 16:1998;593-617
2. Verreck FA, de Boer T, Langenberg DML, et al. IL-23 producing type-1 macrophages promote whereas IL-10 producing type-2 human macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A. 101:2004;4560-4565
3. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 20:2002;197-216
4. Sieling PA, Modlin RL. Toll-like receptors: mammalian "taste receptors" for a smorgasbord of microbial invaders. Curr Opin Microbiol. 5:2002;70-75
5. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 13:1995;251-276
6. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 3:2003;133-146
7. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793
8. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 406:2000;782-787
9. Kawashima T, Kawasaki H, Kitamura T, Nojima Y, Morimoto C. Interleukin-12 induces tyrosine phosphorylation of an 85-kDa protein associated with the interleukin-12 receptor β1 subunit. Cell Immunol. 186:1998;39-44
10. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:2000;715-725
11. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 168:2002;5699-5708
12. Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol. 166:2001;7563-7570
13. Zhang GX, Gran B, Yu S, et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-β2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J Immunol. 170:2003;2153-2160
14. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:2003;744-748
15. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 278:2003;1910-1914
16. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 19:2001;423-474
17. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 16:2002;779-790
18. Sprecher CA, Grant FJ, Baumgartner JW, et al. Cloning and characterization of a novel class I cytokine receptor. Biochem Biophys Res Commun. 246:1998;82-90
19. Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 172:2004;2225-2231
20. Zou W, Borvak J, Marches F, et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J Immunol. 165:2000;4388-4396
21. Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T-cells. Science. 295:2002;338-342
22. Verhagen CE, de Boer T, Smits HH, et al. Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor β1 (IL-12Rβ1): evidence for an IL-12Rβ1-independent pathway of IL-12 responsiveness in human T cells. J Exp Med. 192:2000;517-528
23. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T-cell generation. Nat Immunol. 4:2003;835-842
24. Flyn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 19:2001;93-129
25. Denis M. Killing of Mycobacterium tuberculosis within human monocytes: activation by cytokines and calcitriol. Clin Exp Immunol. 84:1991;200-206
26. Bonecini-Almeida MG, Chitale S, Boutsikakis I, et al. Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-γ and primed lymphocytes. J Immunol. 160:1998;4490-4499
27. Stenger S, Rosat JP, Bloom BR, Krensky AM, Modlin RL. Granulysin: a lethal weapon of cytolytic T-cells. Immunol Today. 20:1999;390-394
28. Ottenhoff TH, Mutis T. Role of cytotoxic cells in the protective immunity against and immunopathology of intracellular infections. Eur J Clin Invest. 25:1995;371-377
29. Reichenbach J, Rosenzweig S, Döffinger R, et al. Mycobacterial diseases in primary immunodeficiencies. Curr Opin Allergy Clin Immunol. 1:2001;503-511
30. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 79:2000;155-169
31. Ottenhoff THM, Verreck FAW, Lichtenauer-Kaligis EGR, et al. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet. 32:2002;97-105
32. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol. 20:2002;581-620
33. Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection. J Clin Invest. 102:1998;2035-2040
34. Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet. 70:2002;336-348
35. Elloumi-Zghal H, Barbouche MR, Chemli J, et al. Clinical and genetic heterogeneity of inherited autosomal recessive susceptibility to disseminated Mycobacterium bovis bacille Calmette-Guérin infection. J Infect Dis. 185:2002;1468-1475
36. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 280:1998;1435-1438
37. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 280:1998;1432-1435
38. Lichtenauer-Kaligis EGR, de Boer T, Verreck FAW, et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor β1 deficient patients and evidence for the existence of partial IL-12 receptor β1 deficiency. Eur J Immunol. 33:2003;59-69
39. Sakai T, Matsuoka M, Aoki M, Nosaka K, Mitsuya H. Missense mutation of the interleukin-12 receptor β1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. Blood. 97:2001;2688-2694
40. Altare F, Ensser A, Breiman A, et al. Interleukin-12 receptor β1 deficiency in a patient with abdominal tuberculosis. J Infect Dis. 184:2001;231-236
41. Aksu G, Tirpan C, Cavusoglu C, et al. Mycobacterium fortuitum-chelonae complex infection in a child with complete interleukin-12 receptor beta 1 deficiency. Pediatr Infect Dis J. 20:2001;551-553
42. Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor β1 deficiency: medical and immunological implications. J Exp Med. 197:2003;527-535
43. Caragol I, Raspall M, Fieschi C, et al. Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor β1 deficiency. Clin Infect Dis. 37:2003;302-306
44. Staretz-Haham O, Melamed R, Lifshitz M, et al. Interleukin-12 receptor β1 deficiency presenting as recurrent Salmonella infection. Clin Infect Dis. 37:2003;137-140
45. Cleary AM, Tu W, Enright A, et al. Impaired accumulation and function of memory CD4 T-cells in human IL-12 receptor β1 deficiency. J Immunol. 170:2003;597-603
46. Jouanguy E, Dupuis S, Pallier A, et al. In a novel form of IFN-γ receptor 1 deficiency, cell surface receptors fail to bind IFN-γ J Clin Invest. 105:2000;1429-1436
47. Allende LM, Lopez-Goyanes A, Paz-Artal E, et al. A point mutation in a domain of gamma interferon receptor 1 provokes severe immunodeficiency. Clin Diagn Lab Immunol. 8:2001;133-137
48. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 335:1996;1941-1949
49. Dorman SE, Holland SM. Interferon-γ and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11:2000;321-333
50. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med. 335:1996;1956-1961
51. Cunningham JA, Kellner JD, Bridge PJ, et al. Disseminated bacille Calmette-Guérin infection in an infant with a novel deletion in the interferon-gamma receptor gene. Int J Tuberc Lung Dis. 4:2000;791-794
52. Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-γ- receptor (IFNγR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol. 27:1999;1368-1374
53. Rosenzweig S, Dorman SE, Roesler J, et al. 561del4 defines a novel small deletion hotspot in the interferon-γ receptor 1 chain. Clin Immunol. 102:2002;25-27
54. Koscielniak E, de Boer T, Dupuis S, et al. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-γ receptor-1 deficiency. Pediatr Infect Dis J. 22:2003;378-380
55. Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-γ, interleukin-12, and tumor necrosis factor-α in human interferon-γ receptor 1 deficiency. J Infect Dis. 178:1998;1095-1104
56. Noordzij JG, Hartwig NG, Verreck FAW, et al. Complete defects in interferon gamma receptor dependent signaling are associated with different clinical phenotypes. Pediatr Res 2004 (in press).
57. Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNγ in a compound heterozygous child. Am J Hum Genet. 62:1998;423-426
58. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-γ receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest. 100:1997;2658-2664
59. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet. 21:1999;370-378
60. Arend SM, Janssen R, Gosen JJ, et al. Multifocal osteomyelitis caused by nontuberculous mycobacteria in patients with a genetic defect of the interferon-γ receptor. Neth J Med. 59:2001;140-151
61. Sasaki Y, Nomura A, Kusuhara K, et al. Genetic basis of patients with bacille Calmette-Guerin osteomyelitis in Japan: identification of dominant partial interferon-γ receptor 1 deficiency as a predominant type. J Infect Dis. 185:2002;706-709
62. Villella A, Picard C, Jouanguy E, et al. Recurrent Mycobacterium avium osteomyelitis associated with a novel dominant interferon gamma receptor mutation. Pediatrics. 107:2001;E47
63. Waibel KH, Regis DH, Uzel G, Rosenzweig SD, Holland SM. Fever and leg pain in a 42-month-old. Ann Alergy Asthma Immunol. 89:2002;239-243
64. Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive IFNγ receptor 1 deficiencies. Lancet 2004 (in press).
65. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J Clin Invest. 101:1998;2364-2369
66. Rosenzweig SD, Dorman SE, Uzel G, et al. A novel mutation in IFN-γ receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol. 173:2004;4000-4008
67. Döffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-γ receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis. 181:2000;379-384
68. Dupuis S, Dargemont C, Fieschi C, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. 293:2001;300-303
69. Dupuis S, Jouanguy E, Al Hajjar S, et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet. 33:2003;388-391
70. Lammas DA, de Heer E, Edgar JD, et al. Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway. Int J Exp Pathol. 83:2002;1-20
71. Döffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signalling. Nat Genet. 27:2001;277-285
72. Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J Clin Invest. 109:2002;1501-1509
73. Courtois G, Smahi A, Reichenbach J, et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest. 112:2003;1108-1115
74. Janssen R, van Wengen A, Hoeve M, et al. The same IκBα mutation in two related individuals leads to completely different clinical syndromes. J Exp Med. 200:2004;559-568
75. Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 299:2003;2076-2079
76. Medvedev AE, Lentschat A, Kuhns DB, et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and Interleukin-1 in a patient with recurrent bacterial infections. J Exp Med. 198:2003;521-531
77. Frucht DM, Holland SM. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection. J Immunol. 157:1996;411-416
78. Haraguchi S, Day NK, Nelson RP Jr, et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A. 95:1998;13125-13129
79. Fieschi C, Casanova JL. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur J Immunol. 33:2003;1461-1464
80. Hoeve MA, de Boer T, Langenberg DML, et al. IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor β1 deficiency. Eur J Immunol. 33:2003;3393-3397
81. Wu C, Wang X, Gadina M, et al. IL-12 receptor β2 (IL-12R β2)-deficient mice are defective in IL-12-mediated signaling despite the presence of high affinity IL-12 binding sites. J Immunol. 165:2000;6221-6228
82. Decken K, Kohler G, Palmer-Lehmann K, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun. 66:1998;4994-5000
83. Brombacher F, Dorfmuller A, Magram J, et al. IL-12 is dispensable for innate and adaptive immunity against low doses of Listeria monocytogenes. Int Immunol. 11:1999;325-332
84. Cooper AM, Kipnis A, Turner J, et al. Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present. J Immunol. 168:2002;1322-1327
85. Gollob JA, Veenstra KG, Jyonouchi H, et al. Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. J Immunol. 165:2000;4120-4126
86. Ortmann R, Smeltz R, Yap G, Sher A, Shevach EM. A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J Immunol. 166:2001;5712-5719
87. Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A. 100:2003;11594-11599
88. Rogge L, Bianchi E, Biffi M, et al. Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet. 25:2000;96-101
89. Colantonio L, Iellem A, Clissi B, et al. Upregulation of integrin α6/β1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T-cells. Blood. 94:1999;2981-2989
90. Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr. 135:1999;640-643
91. Edgar JDM, Smyth AE, Pritchard J, et al. Interferon-γ receptor deficiency mimicking Langerhans' cell histiocytosis. J Pediatr. 139:2001;600-603
92. Dupuis S, Döffinger R, Picard C, et al. Human interferon-γ- mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion. Immunol Rev. 178:2000;129-137
93. MacLennan C, Fieschi C, Lammas DA, et al. Interleukin-(IL)-12 and IL-23 are key cytokines for immunity against salmonella in humans. J Infect Dis. 190:2004;1755-1757
94. Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 103:2004;673-675
95. Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 38:2004;E10-14
96. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med. 345:2001;1098-1104
97. Holland SM. Treatment of infections in the patient with mendelian susceptibility to mycobacterial infection. Microbes Infect. 2:2000;1579-1590
98. Ottenhoff THM, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol Today. 19:1998;491-494
99. Verreck FA, de Boer T, Hoeve M, et al. Human host defense and cytokines in mycobacterial infectious diseases: interleukin-18 cannot compensate for genetic defects in the interleukin-12 system. Clin Infect Dis. 35:2002;210-212
100. Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis inhibits IFN-γ transcriptional responses without inhibiting activation of STAT1. J Immunol. 163:1999;3898-3906
101. Nau GJ, Richmond JF, Schlesinger A, et al. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A. 99:2002;1503-1508
102. Akahoshi M, Nakashima H, Miyake K, et al. Influence of interleukin-12 receptor β1 polymorphisms on tuberculosis. Hum Genet. 112:2003;237-243
103. Remus N, El Baghdadi J, Fieschi C, et al. Association of IL12RB1 polymorphisms with pulmonary tuberculosis in adults in Morocco. J Infect Dis. 190:2004;580-587
104. Marquet S, Schurr E. Genetics of susceptibility to infectious diseases: tuberculosis and leprosy as examples. Drug Metab Dispos. 29:2001;479-483